Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHH-1V Booster in Comirnaty-Vaccinated Adults
NCT05142553Phase 2Completed
- Sponsor
- HIPRA
- Start
- Nov 2021
- Primary completion
- May 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PHH-1V in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by HIPRA. Primary endpoints: Changes of the immunogenicity against Wuhan at 14 days, Safety and tolerability of PHH-1V as third or fourth dose at 7 days and 1 more. Started Nov 2021; status: completed.
02
Drugs
PHH-1V
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05142553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05142553.